What is Essa Pharma's earnings per share (EPS)?

Essa Pharma (EPIX) reported diluted earnings per share of $-0.64 for fiscal year 2024. This represents a -6.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Essa Pharma Financials

EPIX

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE September

This page shows Essa Pharma (EPIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Essa Pharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Essa Pharma generates $0.80 in operating cash flow (-$22.7M OCF vs -$28.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$28.5M

YoY-7.4%

Essa Pharma reported -$28.5M in net income in fiscal year 2024. This represents a decrease of 7.4% from the prior year.

EPS (Diluted)

$-0.64

YoY-6.7%

Essa Pharma earned $-0.64 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 6.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$103.7M

YoY+207.7%

5Y CAGR+14.2%

Essa Pharma held $103.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

44M

YoY+0.7%

5Y CAGR+16.4%

Essa Pharma had 44M shares outstanding in fiscal year 2024. This represents an increase of 0.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-22.9%

YoY-4.7pp

5Y CAGR+3.1pp

Essa Pharma's ROE was -22.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 4.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$21.2M

YoY-0.5%

5Y CAGR+25.9%

Essa Pharma invested $21.2M in research and development in fiscal year 2024. This represents a decrease of 0.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

EPIX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$21.2M-0.5%	$21.3M-12.7%	$24.4M+0.6%	$24.3M+99.7%	$12.1M+81.4%	$6.7M
SG&A Expenses	$13.2M+22.2%	$10.8M-13.8%	$12.5M-2.6%	$12.9M+13.3%	$11.4M+108.5%	$5.5M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$2K+101.4%	-$112K-225.5%	-$34K+88.1%	-$289K-861.2%	$38K
Net Income	-$28.5M-7.4%	-$26.6M+24.3%	-$35.1M+4.6%	-$36.8M-57.0%	-$23.4M-83.8%	-$12.8M
EPS (Diluted)	$-0.64-6.7%	$-0.60+25.0%	$-0.80+16.7%	$-0.96	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$3.5M-36.3%	$5.5M	N/A	$5.5M-11.6%	$6.2M+14.9%	$5.4M	N/A
SG&A Expenses	$5.4M+39.3%	$3.9M-7.4%	$4.2M	N/A	$3.2M-26.4%	$4.3M+94.6%	$2.2M	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.0M+37.2%	-$6.4M+25.3%	-$8.5M	N/A	-$7.2M+19.5%	-$9.0M-50.7%	-$6.0M	N/A
EPS (Diluted)	$-0.09+35.7%	$-0.14	N/A	N/A	$-0.16+20.0%	$-0.20-42.9%	$-0.14	N/A

EPIX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$128.1M-14.1%	$149.1M-12.0%	$169.5M-14.5%	$198.2M+145.9%	$80.6M+47.6%	$54.6M
Current Assets	$127.6M-14.3%	$148.8M-12.0%	$169.1M-14.4%	$197.6M+146.1%	$80.3M+47.9%	$54.3M
Cash & Equivalents	$103.7M+207.7%	$33.7M-41.0%	$57.1M-58.6%	$137.8M+144.7%	$56.3M+5.6%	$53.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M+0.3%	$3.5M+46.4%	$2.4M-42.6%	$4.2M+212.6%	$1.3M-76.2%	$5.6M
Current Liabilities	$3.3M-5.6%	$3.5M+51.3%	$2.3M-41.2%	$3.9M+226.6%	$1.2M-78.4%	$5.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$124.6M-14.4%	$145.6M-12.9%	$167.1M-13.9%	$194.0M+144.8%	$79.2M+61.8%	$49.0M
Retained Earnings	-$208.0M-15.9%	-$179.5M-17.4%	-$152.9M-29.8%	-$117.8M-45.5%	-$81.0M-40.8%	-$57.5M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$110.5M-4.3%	$115.4M-5.9%	$122.6M-4.3%	$128.1M-3.4%	$132.7M-3.8%	$137.9M-4.6%	$144.5M-3.1%	$149.1M
Current Assets	$110.5M-4.1%	$115.2M-5.7%	$122.1M-4.3%	$127.6M-3.4%	$132.1M-3.8%	$137.3M-4.6%	$143.9M-3.3%	$148.8M
Cash & Equivalents	$86.0M-0.4%	$86.3M-7.5%	$93.3M-10.0%	$103.7M+20.6%	$86.0M-6.2%	$91.7M+159.4%	$35.3M+4.9%	$33.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M-14.4%	$1.9M-51.7%	$3.9M+10.3%	$3.5M-7.8%	$3.8M-14.1%	$4.4M+16.3%	$3.8M+8.9%	$3.5M
Current Liabilities	$1.6M-6.7%	$1.7M-53.5%	$3.7M+11.7%	$3.3M-7.7%	$3.6M-14.4%	$4.2M+18.2%	$3.5M+1.0%	$3.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$108.9M-4.1%	$113.5M-4.4%	$118.8M-4.7%	$124.6M-3.3%	$128.9M-3.5%	$133.5M-5.1%	$140.7M-3.4%	$145.6M
Retained Earnings	-$226.9M-1.8%	-$222.9M-2.9%	-$216.5M-4.1%	-$208.0M-3.2%	-$201.6M-3.7%	-$194.4M-4.8%	-$185.4M-3.3%	-$179.5M

EPIX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$22.7M-14.8%	-$19.8M+29.3%	-$28.0M-10.2%	-$25.4M-49.7%	-$17.0M-38.6%	-$12.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$91.8M+2702.4%	-$3.5M+93.4%	-$53.1M-51.5%	-$35.0M-61.1%	-$21.7M-10893.1%	$201K
Financing Cash Flow	$926K+1457.9%	-$68K-127.0%	$253K-99.8%	$142.0M+239.9%	$41.8M-17.4%	$50.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$4.2M+38.7%	-$6.8M-5.9%	-$6.5M-92.2%	-$3.4M+41.4%	-$5.7M+15.7%	-$6.8M-0.5%	-$6.8M-51.2%	-$4.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$3.8M+2598.2%	-$154K+96.1%	-$3.9M-118.7%	$21.0M+89415.0%	$23K-100.0%	$62.5M+659.3%	$8.2M+3210.7%	-$265K
Financing Cash Flow	$0	$0	$0-100.0%	$60K+133.3%	$26K-96.0%	$644K+227.3%	$197K+1540.9%	-$14K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EPIX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-22.9%-4.7pp	-18.3%+2.8pp	-21.0%-2.0pp	-19.0%+10.6pp	-29.6%-3.5pp	-26.0%
Return on Assets	-22.3%-4.5pp	-17.8%+2.9pp	-20.7%-2.1pp	-18.6%+10.5pp	-29.1%-5.7pp	-23.4%
Current Ratio	38.64-3.9	42.57-30.6	73.17+22.9	50.28-16.4	66.73+57.0	9.74
Debt-to-Equity	0.030.0	0.020.0	0.010.0	0.020.0	0.02-0.1	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-3.7%+1.9pp	-5.6%+1.6pp	-7.2%	N/A	-5.6%+1.1pp	-6.7%-2.5pp	-4.2%	N/A
Return on Assets	-3.6%+1.9pp	-5.5%+1.4pp	-7.0%	N/A	-5.5%+1.1pp	-6.5%-2.4pp	-4.1%	N/A
Current Ratio	69.07+1.9	67.17+34.1	33.12-5.5	38.64+1.7	36.95+4.1	32.89-7.9	40.75-1.8	42.57
Debt-to-Equity	0.010.0	0.02-0.0	0.030.0	0.030.0	0.030.0	0.030.0	0.030.0	0.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cyclacel Phar Pr CYCCP

$9.6M

In8Bio, Inc. INAB

$14.2M

Transcode Therapeutics Inc RNAZ

$7.9M

Processa Pharmaceuticals Inc PCSA

$7.4M

Moleculin Biotec MBRX

$12.4M

Frequently Asked Questions

Is Essa Pharma profitable?

No, Essa Pharma (EPIX) reported a net income of -$28.5M in fiscal year 2024.

What is Essa Pharma's return on equity (ROE)?

Essa Pharma (EPIX) has a return on equity of -22.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Essa Pharma's operating cash flow?

Essa Pharma (EPIX) generated -$22.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Essa Pharma's total assets?

Essa Pharma (EPIX) had $128.1M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Essa Pharma spend on research and development?

Essa Pharma (EPIX) invested $21.2M in research and development during fiscal year 2024.

How many shares does Essa Pharma have outstanding?

Essa Pharma (EPIX) had 44M shares outstanding as of fiscal year 2024.

What is Essa Pharma's current ratio?

Essa Pharma (EPIX) had a current ratio of 38.64 as of fiscal year 2024, which is generally considered healthy.

What is Essa Pharma's debt-to-equity ratio?

Essa Pharma (EPIX) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Essa Pharma's return on assets (ROA)?

Essa Pharma (EPIX) had a return on assets of -22.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Essa Pharma's cash runway?

Based on fiscal year 2024 data, Essa Pharma (EPIX) had $103.7M in cash against an annual operating cash burn of $22.7M. This gives an estimated cash runway of approximately 55 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Essa Pharma's Piotroski F-Score?

Essa Pharma (EPIX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Essa Pharma's earnings high quality?

Essa Pharma (EPIX) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.